Leadartis successfully accomplishes the TERET project

07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for Degenerative Retina Diseases) project funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS program. The aim of TERET was the development of the next generation of angiogenic blockers where new compounds with greater efficacy and reduced side effects without compromising eye visual acuity of the patients are essential.

The consortium involved companies and public and private research centers aimed to the identification of potential treatments for the treatment of degenerative diseases of the retina including multivalent antibodies grounded on Leadartis proprietary Trimerbody® technology.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...